This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

Saeed Ahmad, MD, FRCP
Cardio-Diagnostic Clinique Fairmont, WVa

JAMA. 1995;274(16):1266-1267.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

To the Editor.

—Losartan potassium (Cozaar, Merck & Co, Inc, West Point, Pa), the first angiotensin II receptor antagonist, has had labeling approved as an oral treatment for hypertension by the US Food and Drug Administration. It has been marketed by the manufacturer since April 1995. A nonpeptide imidazole derivative, losartan blocks binding of angiotensin II to type I angiotensin II receptors in blood vessels and other tissues; therefore, it inhibits the renin-angiotensin system more selectively and more completely than angiotensin-converting enzyme (ACE) inhibitors. In clinical trials, losartan has been very effective for the treatment of hypertension. The manufacturer states that except for a low incidence of dizziness, losartan has caused no adverse effects at a significantly higher rate than those found with placebo.^1-5 However, I describe herein a patient who developed a severe classic migrainous headache while receiving losartan therapy.

Report of a Case.

—Losartan potassium (50 mg/d) . . . [Full Text PDF of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?